NASDAQ:NMAD Lixte Biotechnology (NMAD) Stock Price, News & Analysis $3.75 -0.03 (-0.79%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Lixte Biotechnology Stock (NASDAQ:NMAD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lixte Biotechnology alerts:Sign Up Key Stats Today's Range$3.68▼$3.8550-Day Range$3.27▼$4.5352-Week Range$2.36▼$8.38Volume66,284 shsAverage Volume215,905 shsMarket Capitalization$60.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lixte Biotechnology Holdings, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies. The company’s research centers on protein phosphatase 2A (PP2A), an enzyme involved in regulating cell growth, survival and response to treatment. Lixte is developing compounds intended to inhibit PP2A and potentially enhance the effectiveness of existing cancer therapies. Lixte’s lead investigational product is LB-100, a small-molecule PP2A inhibitor being evaluated for potential use in combination with chemotherapy, radiation and other anticancer treatments. The company’s development programs are focused primarily on oncology indications, although product candidates remain investigational and are subject to clinical and regulatory review. Lixte Biotechnology Holdings is headquartered in the United States and has historically operated as a research and development company, collaborating with academic and clinical researchers to advance its drug candidates. The company is publicly traded under the symbol LIXT; the symbol NMAD provided in the request does not appear to correspond to Lixte Biotechnology.AI Generated. May Contain Errors. Read More Lixte Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreNMAD MarketRank™: 0.23223864974 of 5 starsLixte Biotechnology scored higher than 5% of companies evaluated by MarketBeat, and ranked 644th out of 655 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLixte Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLixte Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Lixte Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lixte Biotechnology is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lixte Biotechnology is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLixte Biotechnology has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.43% of the float of Lixte Biotechnology has been sold short.Short Interest Ratio / Days to CoverLixte Biotechnology has a short interest ratio ("days to cover") of 4.16.Change versus previous monthShort interest in Lixte Biotechnology has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLixte Biotechnology does not currently pay a dividend.Dividend GrowthLixte Biotechnology does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.73 News SentimentLixte Biotechnology has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lixte Biotechnology this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Lixte Biotechnology to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders7.30% of the stock of Lixte Biotechnology is held by insiders.Percentage Held by Institutions5.10% of the stock of Lixte Biotechnology is held by institutions.Read more about Lixte Biotechnology's insider trading history. Receive NMAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMAD Stock News HeadlinesNOMAD Power Solutions Appoints Michael Hilmer Executive ChairmanNovember 9 at 8:30 AM | globenewswire.comNOMAD Expands Utility Sales Network to 26 States with Two Representative AgreementsOctober 28, 2026 | globenewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)NOMAD POWER SOLUTIONS ANNOUNCES MORE THAN $30 MILLION IN CUSTOMER ORDERS, EXPANDS MANUFACTURING CAPACITY TO SUPPORT GROWTHOctober 15, 2026 | globenewswire.comNOMAD POWER SOLUTIONS LAUNCHES NATIONWIDE MOBILE POWER DEMONSTRATION TOUROctober 6, 2026 | globenewswire.comNOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERSOctober 2, 2026 | globenewswire.comNOMAD Power Solutions Expands Its Canadian Commercial Presence with Appointment of Global Environmental Liquid Ltd. as Sales RepresentativeSeptember 25, 2026 | globenewswire.comNOMAD Power Solutions, Inc.: Nomad Power Solutions Files Expanded Business And Financial Disclosure Following Completion Of MergerSeptember 18, 2026 | finanznachrichten.deSee More Headlines NMAD Stock Analysis - Frequently Asked Questions How have NMAD shares performed this year? Lixte Biotechnology's stock was trading at $3.93 at the beginning of 2026. Since then, NMAD shares have decreased by 4.6% and is now trading at $3.75. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD) issued its quarterly earnings results on Friday, August, 14th. The company reported ($0.16) EPS for the quarter. When did Lixte Biotechnology's stock split? Shares of Lixte Biotechnology reverse split before market open on Monday, June 5th 2023.The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Lixte Biotechnology? Shares of NMAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lixte Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include SoundHound AI (SOUN), Tesla (TSLA), Archer Aviation (ACHR), Imperial Petroleum (IMPP), Super Micro Computer (SMCI), Ford Motor (F) and NIO (NIO). Company Calendar Last Earnings8/14/2026Today11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 4 weeks, NMAD's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Electrical Equipment Sub-IndustryElectrical Components & Equipment Current SymbolNASDAQ:NMAD Previous SymbolNASDAQ:LIXT CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees4Year Founded2006Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.49% Return on Assets-62.03% Debt Debt-to-Equity RatioN/A Current Ratio12.87 Quick Ratio12.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book3.57Miscellaneous Outstanding Shares16,101,000Free Float14,926,000Market Cap$60.38 million OptionableOptionable Beta1.37 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NMAD) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
